Related Experiment Video
Updated: Jul 31, 2026

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
Published on: June 25, 2015
Defective influenza A virus generated entirely from plasmids: its RNA is expressed in infected mouse lung and
1Department of Biological Sciences, University of Warwick, Coventry, UK CV4 7AL.
Abstract:
Naturally produced defective influenza virus has antiviral activity and, in sufficient amount, can protect mice from lethal influenza, irrespective of the virus subtype causing the disease. However, such defective virus preparations contain many undefined defective RNA sequences, and it is thus not possible to establish dose-response relationships. To address this situation, we have transfected DNA encoding a cloned defective RNA into Vero cells along with the 17 A/WSN (H1N1) plasmids required for infectious helper virus, and produced molecularly cloned defective virus. Here we used POLI-220 that expresses a 445 nt defective RNA isolated from a mouse-protective defective equine H3N8 virus, and POLI-317 that expresses a 585 nt defective RNA from an avian H7N7 virus. Both originate from genomic segment 1. Virus preparations were UV-irradiated selectively to destroy virus infectivity but not the activity of the defective RNAs, and adult mice were inoculated intranasally with defective virus and WSN (H1N1) challenge virus (10 LD(50)). Defective POLI-220 and POLI-317 RNAs were detected readily in infected lung tissue by RT-PCR, but these Vero cell preparations did not modulate disease. However, after a single passage in embryonated eggs, defective POLI-220 and POLI-317 viruses significantly delayed the onset of disease and death in WSN-infected mice, although did not affect final mortality. Direct PCR sequencing confirmed the identity of mouse-passaged defective RNAs and showed that none had undergone any sequence changes. With this advance it will now be possible to study the interference phenomenon in vivo with defective viruses carrying a defined defective RNA.
Insights
Molecularly cloned defective influenza viruses expressing defined defective RNAs show antiviral activity. Passage in eggs enhanced their ability to delay disease onset in mice challenged with influenza A virus.
Area of Science:
- Virology
- Immunology
Background:
- Naturally occurring defective influenza viruses exhibit antiviral properties and can protect mice from lethal influenza infections.
- Existing defective virus preparations lack defined RNA sequences, hindering dose-response studies and mechanistic investigations.
Purpose of the Study:
- To produce molecularly cloned defective influenza viruses with defined defective RNAs for in vivo studies.
- To evaluate the antiviral activity and therapeutic potential of these defined defective viruses in a mouse model.
Main Methods:
- Transfection of Vero cells with DNA encoding cloned defective RNAs and helper virus plasmids.
- Production and UV-irradiation of defective virus preparations.
- Intranasal inoculation of mice with defective viruses and subsequent challenge with influenza A virus (WSN/H1N1).
- Detection of defective RNAs by RT-PCR and assessment of disease progression and mortality.
Main Results:
- Vero cell-derived defective viruses (POLI-220 and POLI-317) did not modulate disease in mice.
- A single passage in embryonated eggs significantly delayed disease and death onset in WSN-infected mice.
- Sequence analysis confirmed the integrity of the defective RNAs after passage in vivo.
Conclusions:
- Molecularly cloned defective influenza viruses with defined RNAs can be generated and propagated.
- Passage in embryonated eggs is crucial for enhancing the in vivo antiviral activity of these defined defective viruses.
- This advancement enables precise in vivo studies of the influenza interference phenomenon using defined defective RNAs.
Related Concept Videos
Viral Recombination
Leaky Scanning
Influenza
Inhibitors Of Virion Release

